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Abstract
Previous studies have demonstrated that Marburg viruses (MARV) and Ebola viruses (EBOV) inhibit interferon (IFN)-a/b
signaling but utilize different mechanisms. EBOV inhibits IFN signaling via its VP24 protein which blocks the nuclear
accumulation of tyrosine phosphorylated STAT1. In contrast, MARV infection inhibits IFNa/b induced tyrosine
phosphorylation of STAT1 and STAT2. MARV infection is now demonstrated to inhibit not only IFNa/b but also IFNc-
induced STAT phosphorylation and to inhibit the IFNa/b and IFNc-induced tyrosine phosphorylation of upstream Janus
(Jak) family kinases. Surprisingly, the MARV matrix protein VP40, not the MARV VP24 protein, has been identified to
antagonize Jak and STAT tyrosine phosphorylation, to inhibit IFNa/b or IFNc-induced gene expression and to inhibit the
induction of an antiviral state by IFNa/b. Global loss of STAT and Jak tyrosine phosphorylation in response to both IFNa/b
and IFNc is reminiscent of the phenotype seen in Jak1-null cells. Consistent with this model, MARV infection and MARV VP40
expression also inhibit the Jak1-dependent, IL-6-induced tyrosine phosphorylation of STAT1 and STAT3. Finally, expression
of MARV VP40 is able to prevent the tyrosine phosphorylation of Jak1, STAT1, STAT2 or STAT3 which occurs following over-
expression of the Jak1 kinase. In contrast, MARV VP40 does not detectably inhibit the tyrosine phosphorylation of STAT2 or
Tyk2 when Tyk2 is over-expressed. Mutation of the VP40 late domain, essential for efficient VP40 budding, has no
detectable impact on inhibition of IFN signaling. This study shows that MARV inhibits IFN signaling by a mechanism
different from that employed by the related EBOV. It identifies a novel function for the MARV VP40 protein and suggests
that MARV may globally inhibit Jak1-dependent cytokine signaling.
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Introduction
Filoviruses, which include the genera ebolavirus (EBOV) and
marburgvirus (MARV), are enveloped negative-strand RNA viruses
that cause highly lethal hemorrhagic fever in humans and in non-
human primates. The ability of filoviruses to counteract innate
antiviral responses of the host, particularly the IFNa/b response is
thought to promote uncontrolled virus replication in vivo and
thereby contribute to development of severe disease [1]. The IFNs,
which include IFNa/b and IFNc, are antiviral cytokines. IFNa/b
are members of a family of proteins that interact with the same
ubiquitous receptor to trigger innate antiviral defense mechanisms
and promote adaptive immunity [2]. IFNc also triggers expression
of antiviral genes, however, its major function is to modulate
adaptive immune responses [3]. IFNa/b signaling results in the
tyrosine phosphorylation and activation of the Janus kinases Jak1
and Tyk2. These phosphorylate STAT2 and STAT1, which in
turn heterodimerize and associate with interferon regulatory factor
9 (IRF9) to form a complex that is translocated into the nucleus to
activate genes involved in antiviral response (reviewed in [4]).
IFNc signaling activates Jak1 and Jak2, resulting in tyrosine
phosphorylation of STAT1. This induces STAT1 homodimeriza-
tion and translocation to the nucleus such that IFNc dependent
gene expression is induced (reviewed in [4]). Of note, Jak1, a
kinase involved in multiple cytokine signaling pathways, is critical
for both IFNa/b and IFNc signaling. For example, in cells
lacking Jak1, IFNa/b fails to trigger STAT1 or STAT2 tyrosine
phosphorylation and Tyk2 tyrosine phosphorylation is greatly
reduced or eliminated [5,6]. Similarly, in cells lacking Jak1, IFNc
fails to trigger Jak1, Jak2 or STAT1 tyrosine phosphorylation
[5,7,8].
Filovirus genomes encode seven structural proteins. Four of
these proteins, the nucleoprotein (NP), the viral proteins VP35 and
VP30, and the L protein are tightly associated with the RNA
genome, form the nucleocapsid and mediate replication and
transcription (reviewed in [9]). Besides its function as polymerase
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cofactor, VP35 acts as an inhibitor of antiviral pathways (see
below). Two of the filovirus structural proteins are matrix proteins,
VP40, the functional equivalent of the matrix (M) proteins of other
non-segmented negative-stand RNA viruses, and the minor matrix
protein VP24 that is unique to filoviruses. As a peripheral
membrane protein VP40 is located at the inner side of the virion
membrane. It is critical for viral budding and interacts with
cellular proteins involved in vesicle formation to facilitate virus
release [10,11,12,13,14,15,16,17,18]. The minor matrix protein
VP24 is involved in nucleocapsid formation and assembly
[19,20,21,22,23]. EBOV VP24 plays a crucial role in host tropism
[24,25] and is able to counteract the type I IFN response (see
below). Filoviruses possess a single surface protein, the type I
transmembrane glycoprotein GP that mediates attachment to
target cells and virus entry. Besides EBOV VP35 and VP24,
EBOV GP is the third filoviral protein known to interfere with
antiviral cellular functions [26].
Among filoviruses, IFN evasion strategies have been most
thoroughly explored for EBOVs. The EBOV species Zaire ebolavirus
(ZEBOV) suppresses production of IFNa/b and inhibits cellular
responses to IFNa/b and IFNc [27,28,29,30]. Inhibition of IFNa/b
production appears to be mediated by the VP35 protein [31,32],
whereas cellular responses to IFNa/b and IFNc are blocked by the
EBOV VP24 protein [33,34]. EBOV VP24 prevents the IFN-
induced nuclear accumulation of tyrosine phosphorylated STAT1.
This results in inhibition of IFN-induced gene expression and blocks
the antiviral effects of IFNs. The inhibition of STAT1 nuclear
accumulation is mediated by interaction of VP24 with NPI-1
subfamily of karyopherin a proteins that normally transport
dimerized phospho-STAT1 to the nucleus [33,34].
MARVs have a genome organization similar to EBOVs, but they
are phylogenetically distinct from EBOVs [35]. Despite their similar
genomic organization, morphology and the similarity of MARV
versus EBOV induced disease, several biological differences
between the viruses have been noted, such as differences in their
transcription strategies [36], in the structure of their replication
promoters [37], the use of mRNA editing to express the surface
glycoprotein by EBOVs but not MARVs [38,39] and differences in
the protein requirement for nucleocapsid formation [40,41]. In
terms of the capacity of EBOV and MARV to counteract host IFN
responses, microarray analyses suggest that ZEBOV and MARV
each efficiently suppress host IFN responses, and each virus
effectively inhibits cellular responses to exogenously added IFNa
[30]. However, examination of the phosphorylation status of
STAT1 following addition of IFNa to infected cells revealed an
intriguing difference between ZEBOV andMARV. While ZEBOV
did not inhibit the IFNa-induced tyrosine phosphorylation of
STAT1, MARV infection resulted in an inhibition of both STAT1
and STAT2 tyrosine phosphorylation [30].
The present study demonstrates that MARV infection inhibits
not only IFNa/b but also IFNc and Jak1-dependent IL-6
signaling. Further, the MARV protein mediating these effects
has been identified. We show that expression of the MARV matrix
protein VP40 is sufficient to block IFN and IL-6 signaling
pathways. Experiments in which either Jak1 or Tyk2 are over-
expressed suggest that MARV VP40 targets Jak1 function. These
observations identify an important difference in the biology of
MARV and EBOVs, identify a novel function for a negative-
strand RNA virus matrix protein and suggest that MARV may
inhibit multiple Jak1-dependent cytokine signaling pathways.
Results
MARV infection prevents IFN-mediated phosphorylation
and nuclear translocation of STAT proteins
Previous studies demonstrated that tyrosine phosphorylation of
STAT1 and STAT2 is strongly reduced in MARV- but not in
ZEBOV-infected Huh-7 cells treated with IFNa [30]. To confirm
this observation and to determine whether MARV inhibition
extends to other Jak-STAT signaling pathways, the impact of
MARV infection on IFNa-induced STAT1 and STAT2 phos-
phorylation and on IFNc-induced STAT1 phosphorylation was
compared. As reported, MARV but not EBOV inhibited
phosphorylation of endogenous STAT1 and STAT2 induced by
IFNa (Fig. 1A). MARV also inhibited IFNc-induced STAT1
phosphorylation, whereas EBOV did not (Fig. 1B). For these
studies, immunofluorescence analyses were performed in parallel
to confirm that more than 95% of cells were infected with either
virus (data not shown). These data show that MARV not only
blocks type I but also type II IFN signaling by interfering with an
early step of the Jak-STAT signaling cascade.
Since previous studies indicated that the nuclear translocation of
phosphorylated STAT1 is inhibited in EBOV-infected cells
[33,34], we examined the cellular localization of STAT1 in
MARV-infected cells by immunofluorescence (Fig. 1C). As
expected, STAT1 was translocated into the nucleus in non-
infected cells treated with IFNa (left panels, red staining), whereas
IFNa-induced translocation was inhibited in ZEBOV-infected
cells (right panels, infected cells shown in green). Please note that a
single non-infected cell in the ZEBOV infection panel showed
nuclear accumulation of STAT1. Nuclear translocation of STAT1
was also blocked in MARV-infected cells treated with IFNa
(middle panels).
Taken together, these results highlight a fundamental difference
in the mechanisms by which MARV and EBOV counteract innate
immune responses.
IFNa-induced tyrosine phosphorylation of Janus kinases
is inhibited in MARV-infected cells
Since our data suggested that MARV infection leads to the
inhibition of IFN-induced STAT phosphorylation, we next sought
Author Summary
The closely related members of the filovirus family, Ebola
virus (EBOV) and Marburg virus (MARV), cause severe
hemorrhagic disease in humans with high fatality rates.
Infected individuals exhibit dysregulated immune respons-
es which appear to result from several factors, including
virus-mediated impairment of innate immune responses.
Previous studies demonstrated that both MARV and EBOV
block the type I interferon-induced Jak-STAT signaling
pathway. For EBOV, the viral protein VP24 mediates the
inhibitory effects by interfering with the nuclear translo-
cation of activated STAT proteins. Here, we show that
MARV uses a distinct mechanism to block IFN signaling
pathways. Our data revealed that MARV blocks the
phosphorylation of Janus kinases and their target STAT
proteins in response to type I and type II interferon and
interleukin 6. Surprisingly, the observed inhibition is not
achieved by the MARV VP24 protein, but by the matrix
protein VP40 which also mediates viral budding. Over-
expression studies indicate that MARV VP40 globally
antagonizes Jak1-dependent signaling. Further, we show
that a MARV VP40 mutant defective for budding retains
interferon antagonist function. Our results highlight a
basic difference between EBOV and MARV, define a new
function for MARV VP40 and reveal new targets for the
development of anti-MARV therapies.
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to determine the activation status of Jak1 and Tyk2, the Janus
kinases involved in IFNa-induced phosphorylation of STAT
proteins. Huh-7 cells were infected with MARV or ZEBOV,
treated with IFNa and the phosphorylation state of endogenous
Jak1 and Tyk2 was analyzed by western blot analysis. As shown in
Figure 2A, both kinases were phosphorylated in ZEBOV-infected
cells in response to IFNa, although phosphorylation of Jak1 was
less pronounced compared to non-infected cells (Fig. 2A, compare
lane 2 and 4). However, only background levels of Jak1
phosphorylation were detectable and Tyk2 phosphorylation was
completely blocked in MARV-infected cells treated with IFNa
(Fig. 2A, lane 6). From this we concluded that the inhibition of the
Jak-STAT-signaling pathway by MARV takes place upstream of
Jak phosphorylation or directly at the Janus kinases.
As part of the innate immune response, the Jak-STAT
signaling cascade acts as a first line of defense to prevent viral
infections. Therefore, we determined at which time point of the
MARV replication cycle the observed inhibition of Jak activation
occurs. Further, we asked whether live virus and viral replication
are needed to antagonize IFN signaling. Huh-7 cells were
infected with live MARV or UV-inactivated MARV, treated with
IFNa, harvested at different time points post-infection (p.i.) and
subjected to western blot analysis to determine the phosphory-
lation state of Tyk2. While Tyk2 was still efficiently phosphor-
ylated in MARV-infected and IFN-treated cells at 1 hour and
2.5 hours p.i., respectively, near complete inhibition of Tyk2
phosphorylation was achieved at 4 hours p.i. (Fig. 2B). A single
MARV replication cycle takes approximately 21 hours in Vero
E6 cells [42]. Thus, it can be concluded that the observed
antagonistic effect occurs early in infection. Additionally, since
MARV infection did not lead to the inhibition of Tyk2
phosphorylation at time points earlier than 4 hours p.i., it is
assumed that binding of MARV to its receptor does not trigger its
IFN antagonist function. Interestingly, infection of cells with UV-
inactivated MARV prior to IFNa treatment did not lead to the
inhibition of Tyk2 phosphorylation (Fig. 2B), supporting the
assumption that receptor binding does not play a role in the
MARV-specific inhibition of the IFN signaling cascades. In
addition, these data indicate that intracellular virus replication is
required for the observed antagonistic effects.
To examine whether MARV indirectly inhibits Jak1 phosphor-
ylation via protein tyrosine phosphatases (PTPs), we treated
MARV-infected and IFN-treated cells with different PTP
inhibitors prior to IFNa stimulation. Besides an inhibitor against
PTP1B, which specifically dephosphorylates Tyk2 and Jak2 [43],
we tested the broad acting phosphatase inhibitor sodium
orthovanadate. Our results show that even in the presence of
PTP inhibitors Tyk2 phosphorylation was inhibited in MARV-
infected cells (Fig. 2C), suggesting that the observed inhibitory
effects do not depend on active cellular PTPs.
Figure 1. MARV infection prevents IFN-mediated phosphorylation and nuclear translocation of STAT proteins. Huh-7 cells were
infected with MARV or ZEBOV at an MOI of 5 or mock-infected (Mock). At 24 h p.i., cells were either treated with 100 IU/ml of IFNa-2b (A) or 10 IU/ml
of IFNc (B) for 30 min where indicated. Cell lysates were analyzed by western blotting using antibodies directed against total and phosphorylated
forms of STAT1 (A and B) or STAT2 (A). (C) Huh-7 cells were infected with MARV or ZEBOV at an MOI of 5 or left uninfected. At 24 h p.i., the cells were
stimulated with 1000 IU/ml of IFNa-2b for 45 min, fixed with 4% paraformaldehyde, and stained with antibody directed against STAT1, MARV, or
ZEBOV as indicated.
doi:10.1371/journal.ppat.1000721.g001
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MARV matrix protein VP40 acts as an IFN antagonist
To identify the viral protein mediating the antagonistic effects
observed in MARV-infected cells, individual EBOV or MARV
proteins were assessed for their capacity to counteract the antiviral
effects of IFNb (Fig. 3A). Vero cells were transfected with
expression plasmids; one day post-transfection the cells were
either mock-treated or treated overnight with IFNb, and the cells
were then infected with a Newcastle disease virus that expresses
GFP (NDV-GFP). Since NDV is IFN-sensitive, GFP expression in
these cells provides a measure of virus replication, and suppression
of GFP expression provides a read-out for the antiviral effects of
IFNb. While empty vector (pCAGGS)-transfected, mock-treated
cells permitted NDV-GFP replication, IFNb-treated, empty
vector-transfected cells, in contrast, greatly suppressed GFP
expression (Fig. 3A, panels 1 and 2). As previously described,
expression of Nipah virus W protein, or ZEBOV VP24, known
inhibitors of IFN signaling, rescued replication of NDV-GFP in
IFNb-treated cells [33,44] (Fig. 3A, panel 3 and 4). Surprisingly,
MARV VP24 did not detectably counteract the antiviral effects of
IFNb (Fig. 3A, panel 6). In fact, the only MARV protein tested
that clearly permitted NDV-GFP replication in IFNb-treated cells
was the major matrix protein VP40 (Fig. 3A, panel 9). In contrast,
the homologous ZEBOV protein, ZEBOV VP40, did not support
NDV-GFP replication (Fig. 3A, panel 5).
To confirm the finding that MARV VP40 antagonizes IFN
signaling, we analyzed the intracellular distribution of STAT2 in
cells transiently expressing MARV or EBOV proteins VP35,
VP24, or VP40 (Fig. 3B). Since it has been shown by Brzozka et al.
[45] that rabies virus phosphoprotein (P) efficiently blocks the
nuclear translocation of STAT2 into the nucleus, P was used as a
positive control (Fig. 3B). Cells transfected with empty vector
served as a negative control. While expression of either MARV
VP40 or ZEBOV VP24 led to a significant inhibition of STAT2
accumulation in the nucleus, none of the other tested filoviral
Figure 2. IFNa-induced tyrosine phosphorylation of Janus kinases is inhibited in MARV- but not in EBOV-infected cells. This inhibition
occurs early in infection and is insensitive to PTP inhibitors. (A) Huh-7 cells were infected with MARV or ZEBOV at an MOI of 5 or left uninfected. At 24 h
p.i., cells were treated with 1000 IU/ml of IFNa for 20 min where indicated. Cell lysates were analyzed by western blotting using antibodies directed
against total protein and phosphorylated forms of Jak1 and Tyk2. (B) Huh-7 cells were infected with MARV or UV-inactivated MARV at an MOI of 5 or left
uninfected. 20 min before lysis (24 h p.i.), cells were treated with 2000 IU/ml of IFNa and harvested at the indicated time points. Cell lysates were
analyzed by western blotting using antibodies directed against total protein and phosphorylated forms of Tyk2. (C) Huh-7 cells were infected with
MARV at an MOI of 5. The cells were treated with DMSO (D) or the phosphatase inhibitors sodium orthovanadate (SO) or PTP1B inhibitor (PTP) prior to
IFN treatment (24 h p.i., 2000 IU/ml IFNa for 20 min). Cell lysates were analyzed by western blotting using antibodies directed against total protein and
phosphorylated forms of Tyk2. Note that the cuts in the films excised samples irrelevant to this study.
doi:10.1371/journal.ppat.1000721.g002
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Figure 3. MARV VP40 acts as an IFN antagonist. (A) Vero cells were transfected with 1 mg empty vector (pCAGGS) or the indicated expression
plasmids. 24 h post transfection (p.t.) cells were treated with 1000 IU/ml of IFNb for 24 h and infected with NDV GFP. At 16 h p.i., green fluorescence
(indicating viral replication) was visualized and photographed with a fluorescence microscope. (B) Huh-7 cells were transfected with 2 mg of the
indicated plasmids expressing the indicated viral proteins from rabies virus, ZEBOV and MARV. At 24 h p.t., the cells were stimulated with 2000 IU/ml
of IFNa-2b for 45 min, fixed with 4% paraformaldehyde, and stained with anti-STAT2 antibody and antibodies to detect viral proteins.
doi:10.1371/journal.ppat.1000721.g003
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proteins including ZEBOV VP40 and MARV VP24 was able to
inhibit nuclear translocation of STAT2 in response to IFNa
(Fig. 3B). From this, we concluded that MARV VP40 is the viral
protein interfering with IFN signaling.
MARV VP40 inhibits type I and type II IFN-induced STAT
and Jak activation
Our results obtained with infected cells clearly show that
MARV infection leads to the inhibition of STAT and Jak
phosphorylation, whereas ZEBOV infection does not. To assess
the impact of MARV VP40 on IFN-induced signaling in the
absence of other viral proteins, STAT1-GFP or STAT2-GFP were
co-transfected into Huh-7 cells with empty vector or with plasmids
expressing ZEBOV VP40, ZEBOV VP24, MARV VP40 or
MARV VP24. The phosphorylation state of the STAT proteins in
response to IFNa/b (Fig. 4A) and IFNc (Fig. 4B) was examined by
western blot analysis. Expression of the Langat virus NS5 protein
(LGTV NS5), a protein previously demonstrated to inhibit STAT1
and STAT2 tyrosine phosphorylation [46] served as a control.
Following addition of IFNa/b to transfected Huh-7 cells, MARV
VP40 inhibited the IFNa/b -induced tyrosine phosphorylation of
either STAT1-GFP (Fig. 4A, left panel) or STAT2-GFP (Fig. 4A,
right panel). In contrast, the ZEBOV VP40, ZEBOV VP24 and
MARV VP24 proteins failed to inhibit STAT1 or STAT2 tyrosine
phosphorylation (Fig. 4A). Relative to empty vector-transfected
cells, LGTV NS5 reduced the IFNc-induced phosphorylation of
STAT1-GFP (Fig. 4B), but ZEBOV VP24, MARV VP24 and
ZEBOV VP40 failed to inhibit STAT1 phosphorylation. In
contrast, MARV VP40 expression led to a substantial reduction in
IFNc-induced STAT1 tyrosine phosphorylation (Fig. 4B).
Next, we analyzed the impact of MARV VP40 on the
phosphorylation of Janus kinases in cells treated with IFNa/b or
IFNc. 293T cells were transfected with empty vector or plasmids
that express LGTV NS5, ZEBOV VP24, ZEBOV VP40, MARV
VP24 or MARV VP40, treated with IFNa/b and analyzed for
phosphorylation of endogenous Jak1 and Tyk2. MARV VP40
inhibited the IFNa/b-induced tyrosine phosphorylation of both
kinases (Fig. 4C). Interestingly, none of the other expressed
proteins including LGTV NS5 detectably blocked Jak1 phosphor-
ylation. Although Tyk2 phosphorylation was also reduced by
LGTV NS5 and to a lesser extent by ZEBOV VP24, this
reduction was less pronounced compared to cells expressing
MARV VP40 (Fig. 4C). Similar results were obtained in cells
treated with IFNc. Inhibition of Jak1 and Jak2 phosphorylation in
response to IFNc treatment was only observed in cells expressing
MARV VP40 (Fig. 4D). Taken together, these results clearly
confirm that MARV not only uses a different mechanism than
EBOV to block IFN signaling, but an alternate viral protein
carries out this function.
MARV VP40 inhibits ISRE- and GAS-induced gene
expression
To address the functional significance of the observed
inhibition, the impact of MARV VP40 on IFNb and IFNc-
induced transcription was assessed by reporter gene assay (Fig. 5).
Two reporter constructs were used. One, activated by IFNa/b,
possesses an ISG54 promoter and contains an interferon
stimulated response element (ISRE). The second, activated by
IFNc, possesses three gamma activated sequence (GAS) elements.
293T cells were transfected with either reporter plus expression
plasmids for MARV VP40 or, as controls, MARV VP24 and
ZEBOV VP24. To control for non-specific or cytotoxic effects of
the viral proteins, the results of these assays were normalized to a
co-transfected constitutively-expressed Renilla luciferase reporter
plasmid. MARV VP40 and ZEBOV VP24 inhibited ISG54
promoter activation, whereas MARV VP24 failed to inhibit its
activation (Fig. 5A). Similarly, MARV VP40 inhibited IFNc-
induced gene expression, consistent with its capacity to block IFNc
activation of STAT1. As previously described, ZEBOV VP24
inhibited IFNc-induced gene expression [33], but MARV VP24
did not inhibit gene expression in this assay (Fig. 5B).
The impact of MARV VP40 upon IFNc-induced production of
the 10 kDa interferon-gamma-induced protein (IP-10), an immune
cell chemoattractant protein secreted by several cell types in
response to IFNc, was also assessed. Human umbilical vein
endothelial cells (HUVECs) were transfected with the indicated
expression plasmids, treated with IFNc, and cell supernatants were
tested for the presence of IP-10 by ELISA. MARV VP40 and, to a
lesser extent, ZEBOV VP24 inhibited IP-10 expression, whereas
MARV VP24 did not (Fig. 5C). To assess the specificity of this
effect and exclude cell death or disruption of membrane signaling
components, a similar assay was performed testing the impact of
viral protein expression on TNFa-induced secretion of IL-8 which
is NF-kB-mediated [47,48]. None of the expressed proteins,
including MARV VP40, detectably affected IL-8 production
(Fig. 5D). Therefore the impact of MARV VP40 seems to be
specific for Jak-STAT signaling and does not extend to the
induction of NF-kB-mediated signaling [47].
MARV infection and expression of MARV VP40 inhibit
IL-6-induced STAT1 and STAT3 phosphorylation
Interestingly, our observations are reminiscent of the phenotype
seen in Jak1-deficient cells, where the absence of Jak1 results in loss
of Jak1, Tyk2, STAT1 and STAT2 tyrosine phosphorylation in
response to IFNa/b and loss of Jak1, Jak2 and STAT1 tyrosine
phosphorylation in response to IFNc [5,7,8]. To examine whether
the observed inhibitory effect of MARV on IFN signaling extends
to other, non-IFN, Jak-STAT signaling pathways, we next
analyzed the IL-6-induced activation of STAT1 and STAT3 in
MARV-infected cells and cells expressing VP40. IL-6 was chosen
because, in Jak1-deficient cells, IL-6-induced STAT1 phosphor-
ylation was absent, and STAT3 phosphorylation was greatly
reduced [7]. Huh-7 cells were infected with MARV, treated with
IL-6 at 24 hours p.i. and cell lysates were subjected to western blot
analysis. As shown in Figure 6A, phosphorylation of endogenous
STAT1 was not detectable and STAT3 phosphorylation was
strongly diminished in MARV-infected, IL-6 treated cells,
reflecting the phenotype of Jak1-deficient cells [7]. Similar results
were obtained with transfected Huh-7 cells. MARV VP40
inhibited the IL-6 induced tyrosine phosphorylation of STAT1-
GFP to undetectable levels, and FLAG-STAT3 tyrosine phos-
phorylation was highly reduced (Fig. 6B and C). In contrast,
ZEBOV VP40, ZEBOV VP24 and MARV VP24 did not inhibit
phosphorylation of either STAT1 or STAT3 (Fig. 6B and C).
MARV VP40 inhibits phosphorylation of over-expressed
Jak1
To further assess the capacity of MARV VP40 to target the
function of Jak1, MARV VP40, ZEBOV VP40, MARV VP24 or
ZEBOV VP24 were co-transfected with expression plasmids for
STAT2-GFP and either HA-tagged Jak1 or HA-tagged Tyk2.
Over-expression of Janus kinases leads to their tyrosine phosphor-
ylation [49] and to the phosphorylation of STAT proteins (Fig. 7).
First, we determined the phosphorylation state of HA-Jak1 and
STAT2-GFP in transfected cells by western blot analysis (Fig. 7A).
While MARV VP40 completely inhibited the phosphorylation of
Marburg Virus VP40 Blocks Interferon Signaling
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Figure 4. MARV VP40 inhibits IFN-induced STAT and Jak phosphorylation. (A) STAT1 or STAT2 (1 mg) fused to a C-terminal GFP was co-
expressed in Huh-7 cells with 2 mg of the indicated expression plasmids, treated with 1000 IU/ml of universal IFNa/b for 30 min. Cells were lysed and
assayed by western blot for tyrosine phosphorylated STAT1 (p-STAT1-GFP), STAT2 (p-STAT2-GFP), as well as for total expression levels of over-
expressed proteins. (B) Huh-7 cells were transfected with 2 mg of the indicated expression plasmids and 1 mg of a plasmid expressing STAT1 fused to
GFP at the C-terminus (STAT1-GFP). 24h p.t., cells were treated with 1000 IU/ml of IFNc for 30 min and lysed. Lysates were analyzed by western blot
for phosphorylation of STAT1 and total levels of STAT1 as well as for expression of the tagged proteins. (C and D) 293T cells were transfected with
2 mg of the indicated expression plasmids, treated with 1000 IU/ml of IFNa/b (C) or IFNc (D) for 30 min, lysed and subjected to western blot analysis
for detection of phosphorylated and total Jak1 (C and D), Tyk2 (C) or Jak2 (D). Note that the cuts in the films excised samples irrelevant to this study.
All the presented data for a given protein is from the same gel and the same exposure.
doi:10.1371/journal.ppat.1000721.g004
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over-expressed HA-Jak1 and consequently, the phosphorylation of
STAT2-GFP, ZEBOV VP40, ZEBOV VP24 and MARV VP24
did not show any inhibitory effect (Fig. 7A). Extending this
observation, HA-Jak1 over-expression also led to tyrosine
phosphorylation of endogenous STAT1 and STAT3, and this
was inhibited by MARV VP40 but not by the other tested viral
Figure 5. MARV VP40 inhibits ISRE- and GAS-induced gene expression. (A) MARV VP40 inhibits type I IFN-induced gene expression. 293T
cells were co-transfected with a construct expressing the CAT gene driven by an ISG54 promoter along with a constitutively expressed Renilla
luciferase gene and 1 mg of plasmids that express the indicated viral proteins and 24h.p.t. treated with 1000 IU/ml IFNa/b for 18 h and assayed for
CAT and luciferase activities. The IFN-induced CAT activity was normalized to Renilla luciferase activity. Presented is the mean fold induction of 3
experiments compared to the untreated negative control, error bars represent the standard deviations and the asterisks the p-values (**p-val = 0.016;
***p = 0.0006). Lysates were analyzed for viral protein expression (data not shown). (B) MARV VP40 inhibits IFNc dependent gene expression. Huh-7
cells were co-transfected with the IFNc inducible firefly luciferase reporter plasmid pGAS-Luc along with a constitutively expressed Renilla luciferase
gene and 0.6 mg of the indicated expression plasmids. Cells were treated with a 1000 IU/ml of IFNc for 18 h and assayed for dual luciferase activities.
The IFN-induced firefly luciferase activity was normalized to Renilla luciferase activity. The bars represent the mean fold induction of 3 experiments
compared to the untreated negative control, and the error bars represent the standard deviations. (C) MARV VP40 inhibits the IFNc dependent IP-10
production. 26105 HUVECs were transfected with 2 mg of the indicated expression plasmids. Cells were treated with 100 IU/ml IFNc for 24 h; and
supernatants were collected, cleared by centrifugation and analyzed by ELISA for IP-10. (D) MARV VP40 does not inhibit TNFa-induced IL-8
production. HUVECs were transfected as in (C) and treated with 50 ng/ml of TNFa for 24 h. Supernatants were collected, cleared by centrifugation
and analyzed by ELISA for IL-8 concentrations.
doi:10.1371/journal.ppat.1000721.g005
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proteins (Fig. 7B). In contrast, none of the expressed filovirus
proteins, including MARV VP40, detectably inhibited tyrosine
phosphorylation of over-expressed HA-Tyk2 or Tyk2-induced
STAT2-GFP phosphorylation (Fig. 7C). Further titration of HA-
Tyk2 expression was performed, and phosphorylation of endog-
enous STAT1 was monitored (Fig. 7D). Two-fold dilutions of HA-
Tyk2 plasmid were transfected with either empty vector or MARV
VP40 plasmid. When 500 ng of Tyk2 plasmid was transfected, less
phospho-Tyk2 was detected in the MARV VP40-expressing cells
than in cells receiving empty vector. Similarly, levels of
phosphorylated endogenous STAT1 were decreased in the
presence of MARV VP40. However, the total levels of HA-Tyk2
were also decreased in the presence of MARV VP40 in these
samples (Fig. 7D). Therefore the bands were quantified by
densitometry and the ratio of phosphorylated Tyk2 to total
Tyk2 was calculated for each sample. In all samples the ratios were
in the range of 0.85 to 1.05, suggesting that the decreased levels of
phospho-Tyk2 were due to reduced total levels of Tyk2 (data not
shown). These data support a model where MARV VP40 targets
Jak1 function but do not completely exclude the possibility that
MARV VP40 has a modest capacity to inhibit Tyk2.
MARV VP40 inhibition of Jak1-dependent signaling does
not require an intact late domain
MARV VP40 contains a late domain (PPPY), positioned from
residues 16–19, that mediates VP40 interaction with the cellular
protein Tsg101, a component of the ESCRT I machinery, and
contributes to its budding function [18]. To determine whether
this late domain is critical for MARV VP40 inhibition of signaling,
the 16-PPPY-19 motif was mutated to 16-AAAA-19 (M40-AAAA).
Relative to wild-type EBOV VP40 or wild-type MARV VP40,
M40-AAAA exhibited greatly reduced budding, in the form of
virus-like particles (VLPs), from transfected 293T cells, despite
comparable expression in the whole cell extracts (Fig. 8A). As
expected, a separately expressed GFP was not released into the cell
medium (Fig. 8A). When tested for its ability to suppress IFNa/
b-induced signaling, the mutant suppressed STAT1 phosphoryla-
tion comparably to either LGTV NS5 or wild-type MARV VP40
Figure 6. MARV inhibits IL-6 signaling. (A) Huh-7 cells were infected with MARV at an MOI of 5 or left uninfected. At 24 h p.i., cells were treated
with 50 ng/ml IL-6 for 30 min where indicated. Cell lysates were analyzed by western blotting using antibodies directed against total protein and
phosphorylated forms of STAT1 and STAT3. (B and C) Huh-7 cells were co-transfected with 2 mg of the indicated viral protein expression plasmids and
either 1 mg of plasmids encoding STAT1-GFP (B) or FLAG-STAT3 (C). The samples were analyzed as described in (A). Note that for panels B and C, the
cuts in the films excised samples irrelevant to this study. All the presented data for a given protein is from the same gel and the same exposure.
doi:10.1371/journal.ppat.1000721.g006
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Figure 7. Jak1 phosphorylation is inhibited by MARV VP40. (A and C) 1 mg of HA-tagged human Jak1 (A) or Tyk2 (C) expression plasmid was
transfected into Huh-7 cells along with 2 mg of empty vector (pCAGGS) or the indicated viral protein expression plasmids and 0.5 mg plasmid
encoding STAT2 fused to GFP. Cells were lysed and subjected to western blot analysis using total and phospho-specific antibodies against Jak1 (A),
Tyk2 (C), and STAT2 or GFP. Anti-b-tubulin was used as a loading control and anti-Flag to detect expression of viral proteins. (B) 1 mg of human Jak1
plasmid was transfected along with 2 mg of empty vector (pCAGGS) or the indicated viral protein expression plasmids. Cells were lysed, subjected to
SDS-PAGE and analyzed with total and phospho-specific antibodies against Jak1, STAT1 and STAT3. Anti-b-tubulin was used as a loading control and
anti-Flag to detect expression of viral proteins. (D) Two-fold dilutions of HA-Tyk2 expression plasmid starting at 1 mg were transfected in Huh-7 cells
with either 2 mg of empty plasmid (pCAGGS) or 2 mg of expression plasmid for MARV VP40. Levels of phospho-Tyk2 and phospho-STAT1 as well as
total Tyk2 and STAT1 were assayed by western blot. Anti-b-tubulin and anti-Flag antibodies were used as indicated. Note that for panels A and B, the
cuts in the films excised samples irrelevant to this study. All the presented data for a given protein is from the same gel and the same exposure.
doi:10.1371/journal.ppat.1000721.g007
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Figure 8. MARV VP40 inhibition of IFN signaling does not require an intact late domain. (A) M40-AAAA buds less efficiently than wild type
MARV VP40. A MARV VP40 late domain mutant (M40-AAAA) was made using site directed mutagenesis. M40-AAAA, wild type MARV VP40, ZEBOV
VP40 or GFP (2 mg) was expressed in 293T cells. 48 h later, supernatants were harvested and virus-like particles (VLPs) were purified through a sucrose
cushion. Cells were lysed and examined together with the VLPs for protein expression levels (WCE: whole cell extract). (B) MARV VP40 does not
require the late domain to inhibit the phosphorylation of STAT1. Huh-7 cells were transfected with 1 mg STAT1-GFP expression plasmid along with
2 mg plasmid DNA encoding Flag-tagged versions of viral proteins from LGTV, ZEBOV and MARV or the late domain mutant M40-AAAA and treated
with 1000 IU/ml of IFNa/b for 30 min. Lysates were analyzed for phosphorylation of STAT1 and for total expression levels of all over-expressed
proteins. b-tubulin expression was assessed as indicated. All the presented data for a given protein is from the same gel and the same exposure. (C)
MARV VP40 does not need the late domain to inhibit the IFNa/b-dependent induction of ISG54-Luc. 293T cells were co-transfected with a construct
expressing the luciferase gene under control of an ISG54 promoter along with a constitutively expressed Renilla luciferase reporter gene and 1 mg
empty vector (pCAGGS) or expression plasmids expressing wild-type MARV VP40 or M40-AAAA. Cells were treated with 1000 IU/ml IFNa/b for 18 h
and assayed for firefly and Renilla luciferase activities. IFN-induced firefly luciferase activity was normalized to Renilla luciferase activity. The bars
represent the mean fold induction of 3 experiments compared to the untreated negative control and error bars represent the standard deviations.
doi:10.1371/journal.ppat.1000721.g008
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(Fig. 8B). The mutant also suppressed IFNa/b-induced activation
of the ISG54 promoter comparably to wild-type MARV VP40
(Fig. 8C). Therefore we conclude that the MARV VP40 late
domain is not required for inhibition of signaling.
Discussion
Previous studies have shown that both members of the filovirus
family, MARV and EBOV, impair cellular responses to IFNs
[30,33,34,50]. While ZEBOV blocks the nuclear accumulation of
tyrosine-phosphorylated STAT1 [33,34], the present study
demonstrates that MARV has evolved a different mechanism to
counteract IFN signaling. We show that MARV inhibits the IFNa-
induced tyrosine phosphorylation of not only STAT1 and STAT2
but also of the upstream kinases Jak1 and Tyk2. This inhibition
prevents the IFN-induced nuclear accumulation of STAT1 and
STAT2. Further, MARV infection inhibits the IFNc-induced
tyrosine phosphorylation of STAT1. The inhibition extends even
beyond the IFNa/b and IFNc signaling pathways to another Jak1
dependent signaling pathway, the IL-6 pathway, where the
phosphorylation of STAT1 and STAT3 was inhibited. Signifi-
cantly, the study also identifies a single MARV protein, the matrix
protein VP40, sufficient to mediate these inhibitory effects,
whereas ZEBOV-induced inhibition of IFN signaling is mediated
by VP24 [33]. Emphasizing the specificity of the inhibitory
function for MARV VP40, neither ZEBOV infection nor ZEBOV
VP40 expression impairs Jak or STAT phosphorylation. More-
over, MARV VP24, including VP24s corresponding to the
Musoke strain and the Angola strain, which caused an outbreak
with a very high fatality rate [51], did not detectably inhibit IFNa/
b-induced gene expression (Fig. 5B and data not shown). Musoke
MARV VP24 was also unable to inhibit IFNa/b-, IFNc- or IL-6-
induced phosphorylation of Jaks or STATs.
The striking differences in the strategies employed by filoviruses
to block IFN signaling may have been driven by the different
evolutionary paths taken by Marburg and Ebola viruses. Bayesian
analysis of genome sequence differences indicates that Ebola and
Marburg viruses diverged from a common ancestor several
thousands of years ago (S.T. Nichol, personal communication).
Evolution in and adaptation to different host species might
account for different immune evasion mechanisms. So far, there is
only limited information available about the natural host spectrum
of filoviruses. Various species of African fruit bats were found to be
seropositive or RT-PCR-positive for EBOV [52,53], however, as
yet Ebola viruses have not been isolated from bats. In contrast,
Towner and colleagues reported the successful isolation of MARV
from the Egyptian fruit bat Rousettus aegyptiacus [54]. Since this bat
species is also discussed as a potential reservoir for EBOV [53], it
remains unclear if Marburg and Ebola viruses differ in their host
tropism. Recently, the Asian EBOV species Reston ebolavirus
(REBOV), which is thought to be non-pathogenic for humans,
was isolated from pigs [55]. Phylogenetic analyses suggested that
the REBOV clade has evolved separately from the African Ebola
viruses [55]. Interestingly, REBOV VP24 was also shown to
interfere with the nuclear translocation of STAT1 [34], indicating
that the ability of VP24 to counteract IFN signaling was evolved
among Ebola viruses prior to the separation of the African and
Asian species. Notably, VP24 contributes to the host specificity of
ZEBOV [24,25]. Whether VP40 plays a similar role in MARV
host tropism has yet to be determined; however, it is intriguing
that a mouse-adapted MARV acquired amino acid changes in
VP40 [56].
The effects of MARV infection and MARV VP40 expression on
IFNa/b, IFNc and IL-6 signaling mirror the impact of Jak1
knock-out on these pathways. In cells lacking Jak1, no STAT or
Jak phosphorylation was observed upon IFNa/b or IFNc
treatment [5]. Similarly, the absence of Jak1 profoundly affects
the IL-6 pathway as elimination of Jak1 was sufficient to fully
abrogate any detectable phospho-STAT1 and greatly reduce
phospho-STAT3 following IL-6 addition [7,8]. Interestingly,
MARV infection and individual expression of MARV VP40
closely mirror this phenotype, where following IL-6 addition,
phospho-STAT1 was undetectable but residual phospho-STAT3
was present (Fig. 6). Further studies will reveal to what extent the
observed residual STAT3 phosphorylation may mediate IL-6
signaling.
Our data are consistent with a model in which MARV VP40
targets Jak1 function, either directly or indirectly, although the
possibility remains that MARV VP40 can also impair signaling of
other Jak family kinases. A possible indirect mechanism of the
observed inhibition could be a modulating effect of MARV VP40
on PTPs targeting Jak kinases. Recently, it has been reported that
transgenic mice with reduced expression of the PTP CD45 were
protected against lethal EBOV infection [56]. Interestingly, CD45
acts as a negative regulator of Jak1 in cells of hematopoietic origin
[57]. However, our data suggest that PTPs are not involved in
MARV-mediated inhibition of Jak1 signaling in cells of non-
hematopoietic origin. Therefore, it is of interest to further extend
those studies and to analyze Jak/STAT signaling in human
hematopoietic cells in the context of MARV and EBOV infection.
The observed inhibitory effects of MARV VP40 on both IFNa/
b-induced gene expression and the antiviral effects of IFNb may
explain the capacity of MARV to prevent cellular responses to
exogenously-added IFNa [30]. In this respect, MARV VP40
appears to serve the same purpose as the EBOV VP24 proteins
which also counteract IFNa/b signaling. It is likely that
counteracting IFNa/b signaling has a significant impact on viral
pathogenesis in vivo, because, despite the presence of viral VP35
proteins that suppress IFNa/b production [31,58,59,60], filovirus
replication in vivo results in significant IFNa production [61]. The
presence of IFNa/b signaling inhibitors likely also contributes to
the relative insensitivity of filoviruses to IFNa/b as an antiviral
therapy [50]. IFNc also has antiviral properties [62], however,
suppression of IFNc signaling may also modulate adaptive
immune responses to infection. For example, human cytomega-
lovirus down-regulates Jak1 expression in a proteasome-dependent
manner, and although a specific viral gene product that mediates
this effect has not been defined, this function prevents the IFNc-
induced upregulation of MHC class II on infected cells [63].
Another viral protein that interacts with Jak1 and blocks the type I
IFN signaling pathway is the measles virus V protein, but the
consequence of this function for adaptive immunity has not been
defined [64]. The possible impact of MARV infection and MARV
VP40 expression on other cytokine signaling pathways involving
Jak1 remains to be defined. Given the prominent role of Jak1 in
numerous pathways, the impact of MARV VP40 on cytokine
signaling may be quite broad.
Filovirus VP40 proteins are matrix proteins sufficient to drive
budding of virus-like particles, and they are thought to be the
driving force for the budding of infectious virus
[11,13,18,65,66,67]. The finding that MARV VP40 also serves
as an inhibitor of IFN signaling is surprising and novel. Another
example of a negative-strand RNA virus matrix protein that
inhibits IFN responses is the vesicular stomatitis virus (VSV)
matrix protein (M). VSV M inhibits innate immune responses,
including IFNb production, by a mechanism different from
MARV VP40, inhibiting host cell transcription as well as
nucleo-cytoplasmic transport of cellular mRNAs [68,69,70,71].
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Host factors that interact with filovirus VP40 proteins have
been described [14,18,65,72,73]. The most fully characterized
interactions occur via the VP40 late domain which facilitates
budding and release of virus particles. ZEBOV VP40 possesses
two late domains, a PTAP motif and an overlapping PXXP motif
[11,65]. These mediate interaction with Tsg101, Nedd4, and
Rsp5 [14,65]. MARV VP40 possesses a single PPPY motif that
allows interaction with Tsg101 [18]. To address the potential role
of these well-characterized motifs in MARV VP40 inhibition of
Jak/STAT signaling, a 16-PPPY-19 to 16-AAAA-19 mutant
MARV VP40 was generated. As previously described, this
mutation severely impaired MARV VP40 budding (Fig. 8A)
[18]. Yet this mutation had no detectable impact on MARV
VP40 inhibition of IFNa/b signaling (Fig. 8B and C). Therefore,
the late domain is dispensable for the IFN signaling function of
VP40, and the budding and signaling functions of MARV VP40
appear to be separable. Of note, IFN-induced cellular inhibitors
of filovirus VP40 budding have recently been described. These
include the IFN stimulated ISG15 and tetherin [26,74,75].
ISG15 is an IFN-induced protein which inhibits budding of
EBOV VP40. ISG15 inhibits the ubiquitin ligase Nedd4, which
interacts with EBOV VP40 through the PPXY motif to promote
VP40 ubiquitination and budding [65,75,76]. Tetherin is
constitutively-expressed in some cell types but is also IFN-
inducible. Its expression can prevent release of VLPs produced
following expression of EBOV or MARV VP40 [26,74]. Co-
expression of EBOV GP has been shown capable of counteract-
ing this antiviral function [26]. Whether MARV GP can also
inhibit tetherin has not yet been addressed; however, because
MARV VP40 can inhibit IFN signaling, it appears to have a
built-in capacity to resist IFN-induced mechanisms that target
viral budding.
This study has identified an important difference in the biology
of MARV and EBOV, defined a novel function for the MARV
VP40 matrix protein and suggests that MARV may inhibit
multiple Jak1-dependent cytokine signaling pathways. Future
studies will determine whether the different means by which
EBOV and MARV counteract cell signaling pathways result in
significant differences in the pathologenesis of these viruses.
Determining the molecular mechanisms by which MARV VP40
blocks signaling may facilitate development of new anti-MARV
therapies.
Materials and Methods
Cell lines and viruses
293T, Vero E6, Vero (ATCC, Manassas, VA) and Huh-7
(kindly provided by Dr. DiFeo, Mount Sinai School of Medicine)
cells were maintained in Dulbecco’s modified Eagle medium
(DMEM) supplemented with 10% fetal bovine serum and
10 mM HEPES pH 7.5 or in DMEM supplemented with
penicillin (50 units/ml), streptomycin (50 mg/ml) and 10%
fetal bovine serum. HUVECs were maintained in F-12K
medium (ATCC) supplemented with 0.1 mg/ml heparin
(Sigma-Aldrich, St. Louis, MO), 0.03 mg/ml endothelial cell
growth supplement (ECGS) (Sigma-Aldrich), and 10% fetal
bovine serum (HyClone). A previously-described Newcastle
disease virus engineered to express green fluorescence protein
(NDV-GFP) was propagated in 10-day-old embryonated chicken
eggs [77]. ZEBOV strain Mayinga and MARV strain Musoke
were grown and propagated as described previously [30]. All
work with infectious filoviruses was performed under biosafety
level 4 conditions at the Institute of Virology, Philipps University
of Marburg, Marburg, Germany.
Plasmids
PCR products corresponding to FLAG-tagged, HA-tagged or
untagged viral proteins of EBOV (Accession # NC002549) and
MARV (Accession#NC001608) were cloned into the pCAGGS or
pcDNA3.1 expression vectors [78]. The Nipah Virus W (NiV W)
protein expression plasmid was previously described [77]. The
expression plasmid for V5-tagged Langat Virus NS5 was previously
described [46]. Human Jak1 (Accession # BAE02826) and Tyk2
(Accession # NP_003322) were RT-PCR amplified from RNA
isolated from 293T cells and cloned with an HA tag into the
pCAGGS vector. For the generation of the late domain mutants,
site directed mutagenesis was performed using the QuickChange
XL II kit (Stratagene, La Jolla, CA). A Flag-tagged Rabies P
expression plasmid in a pCR3 background was kindly provided by
Drs. Conzelmann and Brzozka (Ludwig Maximilian University,
Munich, Germany).
Transfections
293T cells were transfected using Lipofectamine 2000 (LF2K) at
a ratio 1:1 with plasmid DNA (mg DNA: mL LF2K). Vero cells
were transfected using LF2K at a ratio 1:2. Huh-7 cells were
transfected using LF2K at a ratio 1:2.75. HUVEC cells were
electroporated using the AMAXA nucleofector II, nucleofection
program V-001 and solution V according to the manufacturer’s
directions (Lonza, Walkersville, MD). Cells were lysed with an
IGEPAL lysis buffer (50 mM Tris [pH 8.0], 280 mM NaCl, 0.5%
IGEPAL, 0.2 mM EDTA, 2 mM EGTA, 10% glycerol, 1 mM
dithiothreitol (DTT) supplemented with protease inhibitor cocktail
(Roche) and 0.1 mM Na3VO4) [79] for 30 min on ice and spun at
13kRPM on a refrigerated tabletop centrifuge for 1 minute.
Cytokines
Universal type I IFN (a consensus IFNa/b), human IFNb and
human IFNc (PBL, Piscataway, NJ) were used at 1000 IU/ml
unless otherwise specified for 30 min in RPMI (GIBCO) or
phosphate buffered saline (PBS) supplemented with 0.3% BSA.
Human IFNa-2b (Essex Pharma, Kenilworth, NJ) diluted in PBS
supplemented with 0.1% BSA was used at 1000–2000 IU/ml
unless otherwise specified. Human TNFa (Peprotech, Rocky Hill,
NJ) was used at 50 ng/ml for 24 hours in HUVEC culture
medium as described above. Human IL-6 (Peprotech, Rocky Hill,
NJ) was used at 50 ng/ml in RPMI supplemented with 0.3% BSA.
Inhibition of IFNb-induced antiviral state
46105 Vero cells per well were cultured in 24 well plates and
transfected with 1 mg of each plasmid encoding viral proteins. At
24 hours post-transfection cells were treated with IFNb (1000 IU/
ml) for 24 hours. Then cells were infected with 5 hemagglutinating
units of NDV-GFP virus in a volume of 200 ml of 0.3% BSA in
PBS for 1 h, washed twice and replaced with DMEM supple-
mented with 10% FBS. GFP expression was visualized at 16 hours
post-infection with a fluorescence microscope.
Reporter gene assays
293T cells (56105) or Huh-7 (36105) were transfected with
0.5 mg of a construct having an IFN-stimulated gene 54 promoter
driving expression of a chloramphenicol acetyltransferase (CAT)
reporter gene (pISG54-CAT), 0.1 mg of a constitutively expressing
Renilla luciferase reporter construct (pCAGGS-luc), and the
indicated amounts of the expression plasmids. Twenty-four hours
post-transfection, cells were washed and treated with IFN (as
described above). Sixteen hours post-IFN treatment, cells were
harvested using reporter lysis buffer (Promega, Madison, WI) and
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analyzed for CAT and luciferase activities by standard methods.
CAT activity was quantified by using a PhosphorImager and
normalized to the luciferase activity. Alternatively, an ISG54-
firefly luciferase reporter plasmid (pISG54-Luc) (0.3 mg) reporter
was used, and a dual luciferase reporter (DLR) assay was
performed according to the manufacturer’s guidelines (Promega).
For IFNc-dependent gene expression, a reporter having 3 copies
of the gamma activated sequence driving the expression of firefly
luciferase (GAS-Luc) (0.3 mg) was transfected with 0.1 mg of a
constitutively expressing luciferase reporter construct (pCAGGS-
luc), and the indicated amounts of the expression plasmids.
Twenty-four hours post-transfection, cells were washed and
treated with IFNc (as described above). Sixteen hours post-IFN
treatment cells were harvested and analyzed using a DLR assay
(Promega). Assays were performed in triplicate and p-values were
calculated by a two-tailed Student’s t-test for unpaired samples
using the software GraphPad Prism (GraphPad Software, Inc.).
Western blot analysis of transfected cells and ELISAs
For the detection of the overexpressed viral proteins, the anti-
V5 (Invitrogen), anti-HA and anti-Flag M2 (Sigma) antibodies
were used at a 1:5000 dilution in 1% non-fat dry milk in Tris-
buffered saline (TBS; 20 mM Tris-HCl, pH 7.4; 150 mM NaCl).
As a loading control, anti beta-tubulin (Sigma) antibody was used
at a 1:10,000 dilution in 1% non-fat dry milk in TBS. Anti-GFP
was used at a 1:10,000 dilution in 1% non-fat dry milk in TBS
(Clontech, Mountain View, CA). Phosphorylated STAT1 was
detected with a phospho-tyrosine specific antibody recognizing
phospho-Y701 (BD Transduction Laboratories, San Jose, CA),
and total levels of STAT1 with an antibody recognizing the
STAT1 C-terminus (BD Transduction Laboratories) diluted to
1:1000 and 1:500, respectively, in 1% non-fat dry milk in TBS.
STAT2 and its phosphorylated form (pY689) were detected with
polyclonal antibodies (Santa Cruz Biotechnology, Santa Cruz, CA
and Upstate, Lake Placid, NY respectively) diluted 1:500 in 1%
non-fat dry milk in TBS. STAT3, pY705-STAT3, Tyk2, pY1054/
1055-Tyk2, pY1022/1023-Jak1, pY1007/1008-Jak2 (Cell Signal-
ing, Beverly, MA), Jak1 (BD Transduction Laboratories) and Jak2
(Millipore, Billerica, MA) were used at a 1:500 dilution in TBS,
0.1% Tween and 5% BSA.
For the detection of IP-10 and IL-8, supernatants of transfected
HUVECs treated with 100 IU/ml human IFNc or 50 ng/ml
TNFa for 24 hours were collected and diluted 1:100 and 1:1000,
respectively, in PBS supplemented with 5% fetal bovine serum.
The BD OptEIA Human IP-10 and Human IL-8 kits were used
(BD Biosciences, Franklin Lakes, NJ).
Western blot analysis of filovirus-infected cells
Huh-7 cells grown in six-well plates to approximately 50%
confluence were infected with ZEBOV or MARV at an MOI of 5.
At 24 hours p.i., cells were left untreated or treated with IFNa-2b
(concentrations indicated in the figure legends), 10 IU/ml IFNc or
50 ng/ml IL-6 for 20 or 30 min, respectively. Where indicated,
filovirus-infected cells were treated with the phosphatase inhibitors
sodium orthovanadate (Sigma; 167 mM, 4 h) or PTPIB-Inhibitor
(Merck; 33 mM, overnight; addition of fresh inhibitor the next
morning for 40 min), or DMSO (Sigma) prior to IFN treatment.
These conditions were shown to be sufficient to block Tyk2
dephosphorylation in non-infected cells treated with IFNa for 60
minutes in the presence of phosphatase inhibitors (data not
shown). Thereafter, cells were washed twice with PBS and scraped
into 26 protein loading buffer (114 mM Tris-HCl, pH 6.8; 2.5%
SDS; 125 mM dithiothreitol; 25% glycerol; 0.25% bromphenol
blue). Cell lysates were transferred to fresh tubes, boiled for 2.5 to
10 min and subjected to SDS-polyacrylamide gel electrophoresis.
Proteins were blotted onto polyvinylidene difluoride membranes,
and the membranes were blocked in 5% non-fat dry milk in TBS
containing 0.1% Tween 20 for 1 hour at room temperature,
followed by an incubation step with the appropriate primary
antibody in TBS supplemented with 5% bovine serum albumin and
0.1% Tween 20 overnight at 4uC. To detect endogenous cellular
proteins, the following antibodies were used: rabbit anti-STAT1-
phospho Tyr 701 (CST; dilution 1:3000), rabbit anti-STAT1-total
(BD transduction; dilution 1:3000), rabbit anti-STAT2-phospho
Tyr 689 (Biomol; dilution 1:1000), rabbit anti-STAT2-total
(Imgenex; dilution 1:1000), rabbit-anti-STAT3-phospho Tyr705
(CST; dilution 1:500), rabbit-anti-STAT3-total (Santa Cruz;
dilution 1:500), rabbit-anti-Tyk2-phospho Tyr1054/1055 (CST;
dilution 1:3000), rabbit-anti-Tyk2-total (Santa Cruz, dilution
1:3000), rabbit-anti-Jak1-phospho Tyr1022/1023 (Biomol; dilution
1:1000) and rabbit-anti-Jak1-total (Santa Cruz; dilution 1:1000).
Horseradish peroxidase-conjugated secondary antibodies (Dianova)
were used and visualized by using either the chemiluminescence
substrate SuperSignal West Dura Extended Duration or Super-
Signal West Femto Maximum Sensitivity (Pierce) according to the
manufacturer’s instructions. To verify virus infection, infected and
IFN-treated cells grown on glass coverslips were subjected to
immunofluorescence analysis using virus-specific antibodies as
described below.
Immunofluorescence analysis
Huh-7 cells grown on glass coverslips were infected with
ZEBOV or MARV at an MOI of 5 or left uninfected. At 24 hours
p.i., cells were washed twice with PBS and inactivated by
treatment with 4% paraformaldehyde for 24 hours. Cells were
then permeabilized with a mixture of acetone and methanol (1:1,
vol/vol) for 5 min at 220uC and treated with 0.1 M glycine. As
primary antibodies, a rabbit antiserum directed against the
nucleocapsid complex of MARV (1:100) and a goat antiserum
directed against ZEBOV (1:500) (kindly provided by Dr. Becker,
Philipps University of Marburg, Marburg, Germany) were used.
To detect endogenous STAT1 or STAT2 proteins in filovirus-
infected cells, the cells were fixed in 4% paraformaldehyde as
described above, washed with 50 mM NH4Cl in PBS and
permeabilized with 0.5% Triton X-100 in PBS. After incubation
with primary antibodies (rabbit anti-STAT1 or rabbit anti-STAT2
(Santa Cruz; dilution 1:100) along with filovirus-specific antibod-
ies), the specimens were washed with PBS and incubated with
fluorescence-labeled secondary antibodies.
To analyze the intracellular localization of endogenous STAT2
in cells expressing individual viral proteins, Huh-7 cells were
transfected with 2 mg of plasmid DNA encoding MARV or
ZEBOV VP40, VP35, or VP24 using FuGene 6 (Roche)
according to the manufacturer’s instructions. VP24 proteins and
ZEBOV VP35 were tagged with an HA epitope. As a control cells
were transfected with 2 mg pCR3 Flag-tagged rabies virus P.
Immunofluorescence analysis was performed by using antibodies
directed against STAT2, MARV VP35 (mouse; 1:100), MARV
VP40 (mouse; 1:100), ZEBOV VP40 (mouse; 1;100), Flag- (Sigma;
dilution 1:700) or HA-tags (Sigma; dilution 1:1000).
VLP budding assay
293T cells were transfected with 2 mg of expression plasmid. At
48 hours post-transfection, cell culture supernatants were clarified
by centrifugation at 2006g for 5 min and pelleted through a 20%
sucrose cushion in NTE buffer (100 mM NaCl, 10 mM Tris
[pH 7.5], 1 mM EDTA [pH 8.0]) at 160,0006g for 2 hours at
4uC. Supernatants were aspirated and the pellets containing the
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virus-like particles (VLPs) were resuspended in NTE buffer. Cells
were washed with PBS and lysed in radioimmunoprecipitation
assay buffer (RIPA) (50 mM Tris [pH 7.4], 150 mM NaCl, 0.1%
sodium dodecyl sulfate [SDS], 0.5% deoxycholate, 1% NP-40)
supplemented with protease inhibitor cocktail (Roche). VLPs and
lysates were analyzed by SDS-PAGE and visualized by western
blotting, as described [80].
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